Homocysteine and ischaemic stroke in men: the Caerphilly study

J Epidemiol Community Health. 2001 Feb;55(2):91-6. doi: 10.1136/jech.55.2.91.

Abstract

Objective: To assess the risk of ischaemic stroke associated with total serum homocyst(e)ine (tHcy) concentration.

Design: Cohort study.

Setting: Caerphilly, South Wales

Participants: 2254 men age 50 to 64 years recruited between 1984 and 1988.

Results: 107 men developed ischaemic stroke and mean follow up time was 10.2 years. There was no significant difference in mean serum total homocyst(e)ine levels between stroke cases (12.2 micromol 95% CI 11.6 to 13.1) and non-cases (11.7 micromol 95% CI 11.5 to 11.9) (p=0.14). There was no significant risk for a standard deviation increase in homocyst(e)ine (adjusted hazard ratio = 1.1, 95% CI 0.9 to 1.4). An interaction was observed between homocyst(e)ine and age at entry (p=0.003). The adjusted odds ratio comparing the top quintile of homocyst(e)ine with the rest was 2.5 (95% CI 1.0 to 6.2) for strokes occurring under 65 years and 0.5 (95% CI 0.2 to 1.3) at 65 years or older (p value for interaction =0.02). Risk also differed by blood pressure status. The adjusted hazard ratio for a standard deviation increase in homocyst(e)ine was 0.8, (95% CI 0.6 to 1.2) for normotensive men and 1.3 (95% CI 1.1 to 1.7) for hypertensive men (p value for interaction =0.01).

Conclusions: Overall, there is no significant relation between homocyst(e)ine and ischaemic stroke in this cohort. However, its aetiological importance may be greater for premature ischaemic strokes (<65 years) and in hypertensive men.

MeSH terms

  • Aged
  • Biomarkers / blood
  • Cohort Studies
  • Homocysteine / blood*
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Risk Factors
  • Stroke / blood*
  • Stroke / epidemiology
  • Stroke / etiology
  • Wales / epidemiology

Substances

  • Biomarkers
  • Homocysteine